Dr. Mitchell Bamberger MD
Attending Physician, TRICOUNTY MEDICAL ASSOCIATES INC
Member of the Healthcare Council
Council Member Biography
Mitchell Bamberger, MD, MBA, FACS, is an Associate Professor of Surgery at the University of Massachusetts Medical School in Worcester, since March 1999. He is also an Attending Physician at TriCounty Urology Associates and Milford Regional Medical Center. Previously, Dr. Bamberger was the Chief of Urology at Saint Vincent Hospital, a 299 bed acute care teaching hospital in Worcester. He has extensive clinical trial investigational experience with the pharmaceutical industry as well being a consultant to a number of medical device manufacturers. Dr. Bamberger is a board member of the Massachusetts Association of Practicing Urologists. He is a reviewer for the journal Urology and has authored over 50 articles, abstracts, and book chapters. Dr. Bamberger's expertise is in business that has allowed him to consult with financial analysts and organizations by presenting both the clinical and financial aspects of medicine and surgery. (This is me - Update Profile)
Employment History
- 2007 - 2008
- Attending Physician, UROLOGY ASSOCIATES OF ESSEX NORTH INC
- 2004 - Unspecified
- Attending Physician, TRICOUNTY MEDICAL ASSOCIATES INC
- 1999 - 2007
- Division Director of Urology, FALLON CLINIC, INC.
- 1999 - Unspecified
- Associate Professor of Surgery, UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
- 1999 - 2007
- Chief of Urology, SAINT VINCENT HOSPITAL, L.L.C.
GLG NewsSM Analyses by Mitchell Bamberger
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Provenge - Do we really have a choice?
November 19, 2010
Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com
Provenge has received FDA clearance for the use in hormone resistant prostate cancer, a disease that kills over 30,000 American men each year. The data says this will extend life for several months on the average, but some may achieve surprising results of regression of disease and even years. The cost is rather high, over $90k for the treatment.
-
Prostate Cancer Genetic Testing - Is it real or is it boutique lab work?
January 20, 2009
Clarient Launches Gene Expression Test for Prostate Cancer | www.medcompare.com
Genetic testing for clinically significant prostate cancer is vital to allow clinicians to treat patients. This appears to be a step in the right direction, although it does not seem this will have a major impact for the majority of cases. The study represents only a small subgroup of patients that may have some benefit from this new molecular biology test.
-
Intermittent hormonal therapy for Prostate Cancer: Is it here yet?
January 2, 2009
Finnish Multicenter Study Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer | www.medicalnewstoday.com
prostate cancer, hormonal therapy, intermittent treatemtent
-
Prostate cancer DNA vaccine trial - a necessary step
December 29, 2008
Approval From The Swedish Medical Products Agency To Start A Clinical Trial Using A Xenogenic PSA DNA Vaccine | www.medicalnewstoday.com
prostate cancer, vaccine, dna
-
Robotic Prostatectomy ?Too soon to tell?
May 29, 2008
Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer. There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities. However, the data does not show a clinical advantage in cancer cure or clinically significant improvement in cancer control. Much more data is needed over a longer period of time. The article does not mention surgeon experience, i.e. those who have done many robotic prostatectomies vs. a surgeon with a limited experience. Nor does the article mention post operative complications such as preservation of erectile function and continence control.
GLG Study Groups with Mitchell Bamberger(?)
GLG Live Meetings with Mitchell Bamberger(?)
Mitchell Bamberger has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.